Products by number of trials

JSON

Products ordered by how many trial records are linked to them from either side. Top 50 of 851 drugs with a value; ties are broken by name. 2,833 of 3,571 trials name at least one product (79%).

#	Treatment	Trials	Status and modality
1	Pembrolizumab	322	approved · Antibody
2	Carboplatin	257	approved · Cytotoxic
3	Cisplatin	180	approved · Cytotoxic
4	Gemcitabine	142	approved · Cytotoxic
5	Paclitaxel / nab-paclitaxel	136	approved · Cytotoxic
6	Pemetrexed	123	approved · Cytotoxic
7	Bevacizumab	119	approved · Antibody
8	Nivolumab	110	approved · Antibody
9	Docetaxel	99	approved · Cytotoxic
10	Durvalumab	88	approved · Antibody
11	Cyclophosphamide	87	approved · Cytotoxic
12	Capecitabine	86	approved · Cytotoxic
13	Doxorubicin	78	approved · Cytotoxic
14	Rituximab	73	approved · Antibody
15	Dexamethasone	69	approved · Hormonal
16	Atezolizumab	64	approved · Antibody
17	Fulvestrant	62	approved · Hormonal
18	Trastuzumab	57	approved · Antibody
19	Lenalidomide	56	approved · Degrader
20	Venetoclax	55	approved · Small molecule
21	Osimertinib	50	approved · Small molecule
22	Oxaliplatin	48	approved · Cytotoxic
23	Cetuximab	47	approved · Antibody
24	Etoposide	46	approved · Cytotoxic
25	Prednisone	45	approved · Hormonal
26	Temozolomide	45	standard-of-care · Cytotoxic
27	Ipilimumab	42	approved · Antibody
28	Trastuzumab deruxtecan	42	approved · Antibody-drug conjugate
29	Vincristine	41	approved · Cytotoxic
30	Olaparib	38	approved · Small molecule
31	Azacitidine	37	approved · Cytotoxic
32	CAPOX (capecitabine, oxaliplatin)	37	standard-of-care · Cytotoxic
33	Fludarabine	37	approved · Cytotoxic
34	Fluorouracil (5-FU)	37	approved · Cytotoxic
35	Cemiplimab	36	approved · Antibody
36	Sacituzumab tirumotecan	36	approved · Antibody-drug conjugate
37	Daratumumab	35	approved · Antibody
38	Toripalimab	35	approved · Antibody
39	Adebrelimab	34	approved · Antibody
40	Bortezomib	34	approved · Small molecule
41	Pertuzumab	34	approved · Antibody
42	PM8002	34	phase-3 · Bispecific or engager
43	Tislelizumab	32	approved · Antibody
44	Abemaciclib	31	approved · Small molecule
45	Enzalutamide	31	approved · Hormonal
46	Palbociclib	31	approved · Small molecule
47	Abiraterone acetate	30	approved · Hormonal
48	Lenvatinib	30	approved · Small molecule
49	Ivonescimab	27	approved · Bispecific or engager
50	Trastuzumab rezetecan	26	approved · Antibody-drug conjugate

801 more drugs have a value below the top 50; the full list of drugs is at /drugs/.

How this is counted

Counts distinct trial records that either name the product in their drugs field or are named in the product's trials field. The context column gives the product's status and modality group.

Coverage. 2,833 of 3,571 trials name at least one product (79%). Rows with a value of zero are not listed. Nothing is weighted, imputed or averaged; the ordering is by the number shown, then by name.

Machine-readable copy: /rankings/drugs-by-trials/data.json. Registry: src/lib/rankings.ts.

Products by number of trials

How this is counted

Other rankings